Citius OncologyCTOR 10 Market Cap is $61.38 Mil as of Jun. 26, 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,023 Drug Manufacturers companies, Citius Oncology ranks worse than 66.37% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Citius Oncology's share price for the quarter that ended in Mar. 2026 was $0.6199. Citius Oncology's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 92.98 Mil. Therefore, Citius Oncology's market cap for the quarter that ended in Mar. 2026 was $57.64 Mil.
Citius Oncology's quarterly market cap
declined
from Sep. 2025 ($169.53 Mil) to Dec. 2025 ($84.80 Mil) and
declined
from Dec. 2025 ($84.80 Mil) to Mar. 2026 ($57.64 Mil).
Citius Oncology's annual market cap
increased
from Sep. 2023 ($0.00 Mil) to Sep. 2024 ($99.46 Mil) and
increased
from Sep. 2024 ($99.46 Mil) to Sep. 2025 ($169.53 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Citius Oncology's Enterprise Value for Today is $62.54 Mil.
Citius Oncology (NAS:CTOR) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Citius Oncology Market Cap Related Terms
Citius Oncology Market Cap Historical Data
* Premium members only.
The historical data trend for Citius Oncology's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Citius Oncology Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's Market Cap distribution charts can be found below:
* The bar in red indicates where Citius Oncology's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Citius Oncology's Market Cap for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Citius Oncology (CTOR) has a Market Cap of $61.38 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Citius Oncology and its competitors. According to the industry distribution chart, Citius Oncology ranks #679 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 66.4%.
Is Citius Oncology's Market Cap too high?
Citius Oncology's current Market Cap is $61.38 Mil. The Drug Manufacturers industry median Market Cap is 206.50. Citius Oncology's value of $61.38 Mil is 70.3% below this industry median. Based on the distribution chart, Citius Oncology ranks #679 out of 1023 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's Market Cap compare to INCR and BGM?
According to the Drug Manufacturers industry distribution chart, Citius Oncology ranks #679 out of 1023 companies for Market Cap. This places Citius Oncology in the lower half of its industry. The industry median Market Cap is 206.50. Citius Oncology's value of $61.38 Mil is 70.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 206.50, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Citius Oncology's current Market Cap of $61.38 Mil is 70.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Citius Oncology and its competitors. For the Drug Manufacturers industry, the median Market Cap is 206.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Oncology's current Market Cap is $61.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current Market Cap of $61.38 Mil. The current Market Cap is $61.38 Mil and 70.3% below the Drug Manufacturers industry median of 206.50. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Citius Oncology (CTOR), the current Market Cap is $61.38 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score
Get the complete analysis for CTOR
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTOR has been successfully added to your 
